Keyphrases
Acute Coronary Syndrome
67%
Acute Myocardial Infarction
18%
All-cause Mortality
26%
Antithrombotic Therapy
17%
Atrial Fibrillation
17%
Bleeding
17%
Cardiomyocytes
14%
Cardiomyogenesis
18%
Clinical Outcomes
14%
Confidence Interval
60%
Coronary Microvascular Obstruction
14%
Dapagliflozin
18%
Duchenne muscular Dystrophy
14%
Edoxaban
18%
Ejection Fraction
18%
Fractional Flow Reserve
18%
Hazard Ratio
15%
Heart Failure
62%
Heart Failure Hospitalization
16%
Heart Failure Patients
14%
Heart Failure with Preserved Ejection Fraction (HFpEF)
16%
Impella
18%
Left Ventricular Assist Device
23%
Left Ventricular Ejection Fraction
14%
Left Ventricular Function
17%
Major Adverse Cardiovascular Events
15%
Meta-analysis
60%
Meta-analysis of Randomized Controlled Trials
23%
Microvascular Obstruction
17%
Myocardial Bridging
23%
Myocardial Infarction
38%
Myocardial Infarction Patients
20%
Myocardium
17%
Myocytes
16%
Non-obstructive Coronary Artery Disease
14%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
15%
Optical Coherence Tomography
19%
Patients with Heart Failure
29%
Percutaneous Coronary Intervention
69%
Percutaneous Endoscopic Gastrostomy
18%
Primary Percutaneous Coronary Intervention
16%
Randomized Controlled Trial
26%
Randomized Trial
14%
Revascularization
23%
Risk Ratio
18%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
18%
ST-elevation Myocardial Infarction (STEMI)
60%
Stent Thrombosis
18%
Systematic Meta-analysis
40%
Type 2 Diabetic Patients
14%
Medicine and Dentistry
Acute Coronary Syndrome
52%
Acute Heart Infarction
14%
Angina pectoris
13%
Antiplatelet
18%
Antithrombotic Therapy
14%
Bleeding
20%
Cardiac Magnetic Resonance Imaging
11%
Cardiac Muscle Cell
18%
Cardiovascular Disease
24%
Cardiovascular System
37%
Clinical Trial
13%
Combination Therapy
11%
Congestive Heart Failure
92%
Coronary Artery
24%
Coronary Artery Disease
26%
Dapagliflozin
18%
Diagnosis
15%
Disease
20%
Drug-Eluting Stent
15%
Duchenne Muscular Dystrophy
11%
Dystrophin
12%
Ejection Fraction
15%
Fractional Flow Reserve
23%
Glucose Uptake
11%
Heart Left Atrium Pressure
14%
Heart Left Ventricle Function
12%
Heart Muscle Ischemia
28%
Heart Ventricle Arrhythmia
12%
Heart Ventricle Remodeling
11%
Infarction
11%
Left Ventricular Assist Device
23%
Meta-Analysis
62%
Myocardial Bridge
23%
Myocardial Disease
14%
Myocardial Infarction
37%
Myocardium
13%
Obstruction
23%
Optical Coherence Tomography
23%
Percutaneous Coronary Intervention
65%
Personalized Medicine
12%
Placebo
13%
Primary Percutaneous Coronary Intervention
15%
Progenitor Cell
23%
Randomized Controlled Trial
22%
Recurrent Disease
11%
Revascularization
25%
Sodium Glucose Cotransporter 2 Inhibitor
11%
ST Segment Elevation Myocardial Infarction
44%
Stent Thrombosis
14%
Systematic Review
41%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
47%
Acute Heart Infarction
18%
All Cause Mortality
19%
Anticoagulant Agent
17%
Antiplatelet
17%
Antithrombotic Therapy
14%
Aortic Regurgitation
9%
Atrial Fibrillation
12%
Biological Marker
12%
Bleeding
25%
Cardiovascular Disease
21%
Chronic Graft Rejection
9%
Clinical Trial
14%
Comorbidity
11%
Congestive Cardiomyopathy
9%
Congestive Heart Failure
100%
Coronary Artery Atherosclerosis
10%
Coronary Artery Disease
20%
Dapagliflozin
18%
Diabetes Mellitus
7%
Direct Oral Anticoagulant
10%
Disease
28%
Duchenne Muscular Dystrophy
9%
Dystrophin
8%
Edoxaban
17%
Heart Disease
7%
Heart Failure with Reduced Ejection Fraction
10%
Heart Infarction
44%
Heart Muscle Ischemia
16%
Heart Right Ventricle Failure
9%
Heart Ventricle Arrhythmia
16%
Heart Ventricle Remodeling
11%
Immunosuppressive Agent
10%
Infarction
8%
Inflammation
17%
Ischemic Heart Disease
17%
Muscular Dystrophy
7%
Myocardial Bridging
14%
Myocardial Disease
11%
Non Insulin Dependent Diabetes Mellitus
18%
Obstruction
14%
Pathophysiology
7%
Pharmacotherapy
7%
Placebo
17%
Randomized Controlled Trial
32%
Scar Formation
9%
Sodium Glucose Cotransporter 2 Inhibitor
18%
ST Segment Elevation Myocardial Infarction
21%
Syndrome
8%
Thromboembolism
8%
